-
Product Insights
New![]()
Net Present Value Model: Mustang Bio Inc’s MB-107
Overview Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
New![]()
Net Present Value Model: Mustang Bio Inc’s MB-106
Overview Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
Unitized MB Unit Field, Indonesia
Unitized MB Unit upstream field is located in West Java, Indonesia. The upstream field is owned by Pertamina Hulu Energi ONWJ. It is operated by Pertamina Hulu Energi ONWJ. The project started its operations in 2016. Unitized MB Unit Upstream Field profile includes core details such as name, resource type, asset status, stage, owner and equity stakes, operator, product specs (gravity, CO2, sulphur), location, as well as key operational data including production, start and end years, reserves and capital and...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – MBS-2320 in Autoimmune Disorders
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. MBS-2320 in Autoimmune Disorders Drug Details: MBS-2320 is under development for the treatment of rheumatoid...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – MB-103 in Brain Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.MB-103 in Brain CancerDrug Details:MB-103 is under development for the treatment of glioblastoma multiforme, breast cancer...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – MB-106 in Burkitt Lymphoma
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. MB-106 in Burkitt Lymphoma Drug Details: MB-106 is under investigation for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – MB-106 in Follicular Lymphoma
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. MB-106 in Follicular Lymphoma Drug Details: MB-106 is under investigation for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – MB-103 in Glioblastoma Multiforme (GBM)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.MB-103 in Glioblastoma Multiforme (GBM)Drug Details:MB-103 is under development for the treatment of glioblastoma multiforme, breast...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – MB-107 in X-Linked SCID
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.MB-107 in X-Linked SCIDDrug Details:MB-107 is under development for the treatment of X-linked severe combined immunodeficiency....
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – MB-106 in Mantle Cell Lymphoma
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. MB-106 in Mantle Cell Lymphoma Drug Details: MB-106 is under investigation for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – MB-106 in Hairy Cell Leukemia
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. MB-106 in Hairy Cell Leukemia Drug Details: MB-106 is under investigation for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – MBS-2320 in Idiopathic Pulmonary Fibrosis
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. MBS-2320 in Idiopathic Pulmonary Fibrosis Drug Details: MBS-2320 is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – MB-CART 19.1 in Systemic Lupus Erythematosus
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. MB-CART 19.1 in Systemic Lupus Erythematosus Drug Details: MB-CART 19.1 is under development for...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – MB-106 in Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma)
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. MB-106 in Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) Drug Details: MB-106 is under investigation for the...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – MB-106 in Marginal Zone B-cell Lymphoma
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. MB-106 in Marginal Zone B-cell Lymphoma Drug Details: MB-106 is under investigation for the...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – MB-106 in Primary Mediastinal B-Cell Lymphoma
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. MB-106 in Primary Mediastinal B-Cell Lymphoma Drug Details: MB-106 is under investigation for the...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – MB-106 in Diffuse Large B-Cell Lymphoma
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. MB-106 in Diffuse Large B-Cell Lymphoma Drug Details: MB-106 is under investigation for the...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – MB-106 in Relapsed Chronic Lymphocytic Leukemia (CLL)
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. MB-106 in Relapsed Chronic Lymphocytic Leukemia (CLL) Drug Details: MB-106 is under investigation for...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – MB-106 in Refractory Chronic Lymphocytic Leukemia (CLL)
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. MB-106 in Refractory Chronic Lymphocytic Leukemia (CLL) Drug Details: MB-106 is under investigation for...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – MB-106 in B-Cell Non-Hodgkin Lymphoma
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. MB-106 in B-Cell Non-Hodgkin Lymphoma Drug Details: MB-106 is under investigation for the treatment...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.